The Gamaleya National Research Center for Epidemiology and Microbiology has begun developing an analogue of the SARS-CoV-2 coronavirus drug, which was used by President of the United States Donald Trump. This was announced to reporters by the director of the Gamaleya center Alexander Gintsburg.
Follow the developments in the broadcast: "Coronavirus in Russia: New Year with signs of stabilization"
We are talking about the development of a drug based on monoclonal antibodies. These are antibodies that protect against the virus and are found in the plasma of those who have had COVID-19. But they will be obtained by genetic engineering, outside the human body, and in a concentrated form, Gunzburg explained. The drug may appear as early as the end of 2021.
It is worth noting that US President Donald Trump was treated with a similar drug for coronavirus. It is also very common to administer COVID-19 patients in a severe form of blood plasma to those who have previously had a coronavirus infection.
In addition, Gunzburg said that the Gamaleya Center is working on a vaccine that would simultaneously protect against influenza and coronavirus. The technologies available to the center make it possible to create a drug for different strains of the same pathogen or for different viruses.
Among other things, Gunzburg said that the specialists of his center are creating "chemistry that should protect against nosocomial infections." It is known that nosocomial infections have become a very serious problem - due to the massive use of antibiotics, many pathogens have become resistant to any antibiotic. Gunzburg recalled that nosocomial infections became the main factor in the death of patients with COVID-19 in the hospital.